Results 41 to 50 of about 211,280 (349)

Current status and future perspectives of platelet function-guided precision antiplatelet therapy for patients with cerebral infarction. [PDF]

Neuroprotection
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Zhu G, Chen X, Huang X, Tan Q, Cao Q, Yang Y, Lin Y, Yang J.   +7 more
europepmc   +2 more sources

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2019
Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option.
Hirotoshi Watanabe, T. Domei, T. Morimoto, M. Natsuaki, H. Shiomi, T. Toyota, M. Ohya, S. Suwa, K. Takagi, M. Nanasato, Yoshiki Hata, Masahiro Yagi, Nobuhiro Suematsu, Takafumi Yokomatsu, I. Takamisawa, M. Doi, T. Noda, H. Okayama, Yoshitane Seino, T. Tada, H. Sakamoto, K. Hibi, M. Abe, K. Kawai, Koichi Nakao, K. Ando, K. Tanabe, Y. Ikari, K. Hanaoka, Y. Morino, K. Kozuma, K. Kadota, Y. Furukawa, Y. Nakagawa, Takeshi Kimura   +34 more
semanticscholar   +1 more source

Antiplatelet agents for preventing pre-eclampsia and its complications.

Cochrane Database of Systematic Reviews, 2019
BACKGROUND Pre-eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses that
L. Duley, S. Meher, K. Hunter, A. Seidler, L. Askie   +4 more
semanticscholar   +1 more source

Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines

Stroke and vascular neurology, 2022
Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review aimed to highlight the current evidence and recommendations of antiplatelet therapy for stroke prevention.
Jay Shah, Shi-Meng Liu, Wen-Gui Yu
semanticscholar   +1 more source

Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review

Health Technology Assessment, 2013
Background: Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular ...
DA Lane, S Raichand, D Moore, M Connock, A Fry-Smith, DA Fitzmaurice, on behalf of the Steering Committee   +6 more
doaj   +1 more source

Laparoscopic total extraperitoneal inguinal hernia repair is safe and feasible in patients with continuation of antithrombotics

Journal of Minimal Access Surgery, 2019
Aims: We aimed to evaluate the safety and feasibility of laparoscopic total extraperitoneal (TEP) inguinal hernia repair in patients with the continuation of their antithrombotic agents. Settings and Design: This was prospective cohort study.
Chen-Hsun Ho, Chia-Chang Wu, Chao-Chuan Wu, Yao-Chou Tsai   +3 more
doaj   +1 more source

Effects of Periprocedural Tirofiban vs. Oral Antiplatelet Drug Therapy on Posterior Circulation Infarction in Patients With Acute Intracranial Atherosclerosis-Related Vertebrobasilar Artery Occlusion

Frontiers in Neurology, 2020
Background and purpose: Tirofiban and oral antiplatelet drugs can be used to inhibit reocclusion and restore microvascular reperfusion during endovascular treatment (EVT).
Xuan Sun, Huijun Zhang, Xu Tong, Feng Gao, Gaoting Ma, Zhongrong Miao   +5 more
doaj   +1 more source

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy

Frontiers in Cardiovascular Medicine, 2022
Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin remains the standard of care for all patients undergoing percutaneous coronary intervention (PCI).
Anh Nguyen, L. Cavallari, J. Rossi, G. Stouffer, Craig R. Lee   +4 more
semanticscholar   +1 more source

Drug interactions and hepatotoxicity of clopidogrel [PDF]

, 2010
Clopidogrel (Plavix¨) is an antiplatelet drug, which is clinically used in combination with aspirin to reduce cardiovascular events in patients undergoing percutaneous coronary intervention or in patients suffering from acute coronary syndromes ...
Zahno, Anja-Christina
core   +1 more source

Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention [PDF]

, 2020
Complex percutaneous coronary intervention (PCI) patients are a high-risk population for ischemic complications. Antiplatelet therapy in such patients remains controversial, as the beneficial effects of more potent agents use or prolonged dual ...
Dimitrios Alexopoulos, Charalampos Varlamos, Despoina-Rafailia Benetou   +2 more
core   +1 more source